Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CORT Corcept Therapeutics	$100.48 +83.9%	$61.89	$20.84 ▼ $109.27	$10.62B	0.61	1.02 million shs	7.47 million shs
JAZZ Jazz Pharmaceuticals	$123.37 +0.4%	$132.30	$99.06 ▼ $148.06	$7.49B	0.44	901,244 shs	343,154 shs
RPRX Royalty Pharma	$30.87 -1.6%	$32.44	$24.05 ▼ $34.20	$17.79B	0.47	3.10 million shs	1.96 million shs
ZTS Zoetis	$162.77 -0.2%	$166.40	$144.80 ▼ $200.33	$72.89B	0.94	2.97 million shs	449,839 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CORT Corcept Therapeutics	0.00%	-6.87%	-9.82%	+7.43%	+116.87%
JAZZ Jazz Pharmaceuticals	0.00%	-11.42%	-14.36%	-0.04%	+2.08%
RPRX Royalty Pharma	0.00%	-6.91%	-6.75%	+23.89%	+3.29%
ZTS Zoetis	0.00%	+0.10%	-2.72%	+0.49%	-3.65%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CORT Corcept Therapeutics	3.2384 of 5 stars	1.5	0.0	0.0	4.3	1.9	4.2	1.9
JAZZ Jazz Pharmaceuticals	4.9108 of 5 stars	4.5	1.0	0.0	4.0	4.0	2.5	3.1
RPRX Royalty Pharma	4.8307 of 5 stars	3.5	3.0	2.5	3.7	3.5	1.7	2.5
ZTS Zoetis	4.5913 of 5 stars	3.5	3.0	4.2	0.4	3.6	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CORT Corcept Therapeutics	3.00	Buy	$99.75	-0.72% Downside
JAZZ Jazz Pharmaceuticals	2.93	Moderate Buy	$187.71	52.16% Upside
RPRX Royalty Pharma	3.00	Buy	$41.60	34.78% Upside
ZTS Zoetis	3.08	Buy	$215.90	32.64% Upside

Current Analyst Ratings Breakdown

Latest RPRX, ZTS, JAZZ, and CORT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/28/2025	RPRX Royalty Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/10/2025	JAZZ Jazz Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$200.00 ➝ $217.00
3/7/2025	JAZZ Jazz Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$175.00 ➝ $183.00
3/7/2025	JAZZ Jazz Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$145.00 ➝ $179.00
3/6/2025	JAZZ Jazz Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$220.00 ➝ $230.00
3/5/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$210.00 ➝ $210.00
2/27/2025	JAZZ Jazz Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$190.00 ➝ $200.00
2/27/2025	CORT Corcept Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$67.00 ➝ $78.00
2/27/2025	CORT Corcept Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$115.00 ➝ $115.00
2/27/2025	ZTS Zoetis	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$200.00 ➝ $205.00
2/26/2025	JAZZ Jazz Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$140.00 ➝ $150.00

(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CORT Corcept Therapeutics	$675.04M	15.70	$1.48 per share	67.96	$4.92 per share	20.42
JAZZ Jazz Pharmaceuticals	$4.07B	1.84	$25.13 per share	4.91	$59.36 per share	2.08
RPRX Royalty Pharma	$2.26B	7.86	$3.89 per share	7.94	$17.94 per share	1.72
ZTS Zoetis	$9.26B	7.87	$7.31 per share	22.26	$10.65 per share	15.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CORT Corcept Therapeutics	$106.14M	$1.24	79.87	54.31	N/A	22.35%	24.54%	20.24%	4/29/2025 (Estimated)
JAZZ Jazz Pharmaceuticals	$414.83M	$8.79	17.37	6.59	1.04	11.60%	29.30%	9.72%	4/29/2025 (Estimated)
RPRX Royalty Pharma	$858.98M	$1.45	21.29	6.35	2.31	37.94%	24.40%	14.01%	5/8/2025 (Estimated)
ZTS Zoetis	$2.49B	$5.47	29.76	24.11	2.78	26.86%	53.82%	18.86%	5/6/2025 (Estimated)

Latest RPRX, ZTS, JAZZ, and CORT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
2/26/2025	Q4 2024	CORT Corcept Therapeutics	$0.37	$0.26	-$0.11	$0.26	$200.12 million	$181.89 million
2/13/2025	Q4 2024	ZTS Zoetis	$1.37	$1.40	+$0.03	$1.29	$2.30 billion	$2.32 billion
2/11/2025	Q4 2024	RPRX Royalty Pharma	$0.99	$1.15	+$0.16	$0.35	$743.60 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RPRX Royalty Pharma	$0.88	2.85%	+7.30%	60.69%	N/A
ZTS Zoetis	$2.00	1.23%	+18.66%	36.56%	14 Years

Latest RPRX, ZTS, JAZZ, and CORT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/6/2025	ZTS Zoetis	quarterly	$0.50	1.2%	4/21/2025	4/21/2025	6/3/2025
1/9/2025	RPRX Royalty Pharma	quarterly	$0.22	2.8%	2/21/2025	2/21/2025	3/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CORT Corcept Therapeutics	0.01	3.70	3.64
JAZZ Jazz Pharmaceuticals	1.46	4.26	3.74
RPRX Royalty Pharma	0.64	1.44	1.44
ZTS Zoetis	1.09	1.75	1.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CORT Corcept Therapeutics	93.61%
JAZZ Jazz Pharmaceuticals	89.14%
RPRX Royalty Pharma	54.35%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
CORT Corcept Therapeutics	20.50%
JAZZ Jazz Pharmaceuticals	4.20%
RPRX Royalty Pharma	18.90%
ZTS Zoetis	0.16%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CORT Corcept Therapeutics	300	105.50 million	83.30 million	Optionable
JAZZ Jazz Pharmaceuticals	3,200	60.73 million	57.92 million	Optionable
RPRX Royalty Pharma	80	576.45 million	477.83 million	Optionable
ZTS Zoetis	14,100	447.79 million	447.08 million	Optionable

RPRX, ZTS, JAZZ, and CORT Headlines

Recent News About These Companies

Zoetis Inc. (NYSE:ZTS) Shares Sold by Clearbridge Investments LLC

March 31 at 7:20 AM | marketbeat.com

CIBC Private Wealth Group LLC Decreases Stock Holdings in Zoetis Inc. (NYSE:ZTS)

March 31 at 6:41 AM | marketbeat.com

Martin Currie Ltd. Reduces Stock Holdings in Zoetis Inc. (NYSE:ZTS)

March 31 at 6:39 AM | marketbeat.com

Allstate Corp Invests $2.19 Million in Zoetis Inc. (NYSE:ZTS)

March 31 at 5:11 AM | marketbeat.com

DnB Asset Management AS Raises Position in Zoetis Inc. (NYSE:ZTS)

March 31 at 5:02 AM | marketbeat.com

Rep. Robert Bresnahan, Jr. Sells Zoetis Inc. (NYSE:ZTS) Stock

March 30 at 8:03 AM | marketbeat.com

State Farm Mutual Automobile Insurance Co. Sells 26,093 Shares of Zoetis Inc. (NYSE:ZTS)

March 30 at 6:58 AM | marketbeat.com

Brown Brothers Harriman & Co. Decreases Stock Holdings in Zoetis Inc. (NYSE:ZTS)

March 30 at 6:13 AM | marketbeat.com

Orion Portfolio Solutions LLC Buys 5,447 Shares of Zoetis Inc. (NYSE:ZTS)

March 30 at 5:53 AM | marketbeat.com

New Age Alpha Advisors LLC Purchases Shares of 24,838 Zoetis Inc. (NYSE:ZTS)

March 30 at 5:35 AM | marketbeat.com

UniSuper Management Pty Ltd Has $5.08 Million Stake in Zoetis Inc. (NYSE:ZTS)

March 30 at 5:10 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Receives Consensus Recommendation of "Buy" from Brokerages

March 30 at 2:19 AM | marketbeat.com

Alerus Financial NA Lowers Position in Zoetis Inc. (NYSE:ZTS)

March 29 at 7:11 AM | marketbeat.com

denkapparat Operations GmbH Invests $373,000 in Zoetis Inc. (NYSE:ZTS)

March 29 at 6:57 AM | marketbeat.com

Pictet Asset Management Holding SA Acquires 455,191 Shares of Zoetis Inc. (NYSE:ZTS)

March 29 at 6:48 AM | marketbeat.com

Broadway Wealth Solutions Inc. Takes $273,000 Position in Zoetis Inc. (NYSE:ZTS)

March 29 at 6:40 AM | marketbeat.com

Norges Bank Invests $824.32 Million in Zoetis Inc. (NYSE:ZTS)

March 29 at 6:05 AM | marketbeat.com

Caisse Des Depots ET Consignations Makes New $311,000 Investment in Zoetis Inc. (NYSE:ZTS)

March 29 at 6:05 AM | marketbeat.com

NEOS Investment Management LLC Increases Stock Holdings in Zoetis Inc. (NYSE:ZTS)

March 29 at 5:38 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Elo Mutual Pension Insurance Co

March 29 at 5:29 AM | marketbeat.com

Zoetis (ZTS) Stock Moves -1.16%: What You Should Know

March 28 at 9:49 PM | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPRX, ZTS, JAZZ, and CORT Company Descriptions

Corcept Therapeutics NASDAQ:CORT

$100.22 +45.59 (+83.44%)

As of 11:26 AM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Jazz Pharmaceuticals NASDAQ:JAZZ

$123.21 +0.29 (+0.23%)

As of 11:26 AM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Royalty Pharma NASDAQ:RPRX

$30.86 -0.51 (-1.64%)

As of 11:26 AM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Zoetis NYSE:ZTS

$162.73 -0.38 (-0.23%)

As of 11:26 AM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time